STERIS plc $STE Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. lowered its stake in shares of STERIS plc (NYSE:STE) by 9.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 172,396 shares of the medical equipment provider’s stock after selling 18,799 shares during the quarter. Federated Hermes Inc.’s holdings in STERIS were worth $42,658,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in STERIS by 1.7% in the 2nd quarter. Vanguard Group Inc. now owns 12,163,128 shares of the medical equipment provider’s stock valued at $2,921,827,000 after buying an additional 205,276 shares during the period. State Street Corp boosted its holdings in shares of STERIS by 2.4% in the second quarter. State Street Corp now owns 4,188,103 shares of the medical equipment provider’s stock valued at $1,006,069,000 after acquiring an additional 98,220 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of STERIS by 1.9% in the second quarter. Geode Capital Management LLC now owns 2,479,108 shares of the medical equipment provider’s stock valued at $592,980,000 after acquiring an additional 46,859 shares in the last quarter. Orbis Allan Gray Ltd increased its stake in shares of STERIS by 36.0% during the second quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider’s stock worth $504,486,000 after acquiring an additional 556,088 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in STERIS by 3.9% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,346,039 shares of the medical equipment provider’s stock worth $323,345,000 after purchasing an additional 50,764 shares in the last quarter. 94.69% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, VP John Adam Zangerle sold 15,000 shares of STERIS stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $265.14, for a total transaction of $3,977,100.00. Following the completion of the transaction, the vice president owned 33,669 shares of the company’s stock, valued at $8,926,998.66. The trade was a 30.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Julia Madsen sold 5,008 shares of the business’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $262.00, for a total transaction of $1,312,096.00. Following the completion of the sale, the vice president owned 10,710 shares in the company, valued at $2,806,020. This represents a 31.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 25,044 shares of company stock valued at $6,586,218. 1.07% of the stock is owned by insiders.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $273.50.

STERIS Stock Performance

Shares of STE opened at $261.86 on Friday. The company has a quick ratio of 1.63, a current ratio of 2.37 and a debt-to-equity ratio of 0.27. STERIS plc has a 52-week low of $204.90 and a 52-week high of $269.44. The company has a 50-day simple moving average of $259.31 and a 200-day simple moving average of $248.35. The company has a market capitalization of $25.70 billion, a PE ratio of 37.62 and a beta of 1.03.

STERIS (NYSE:STE) last issued its earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.38 by $0.09. STERIS had a net margin of 12.07% and a return on equity of 14.43%. The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. During the same period in the prior year, the business posted $2.14 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. Equities research analysts predict that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Investors of record on Tuesday, February 17th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Tuesday, February 17th. This represents a $2.52 annualized dividend and a yield of 1.0%. STERIS’s payout ratio is currently 36.21%.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.